Comment
Author: Admin | 2025-04-28
5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter; dose may be increased to 10 mg/kg in patients who respond but then lose their response. If no response by week 14, consider discontinuing therapy.Crohn disease management after surgical resection (off-label use): IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter (Armuzzi 2013; Regueiro 2009; Singh 2015) or 5 mg/kg every 8 weeks (Regueiro 2016; Yoshida 2012). Note: Administer first infusion within 4 weeks after surgery in high-risk patients (Lichtenstein 2018).Plaque psoriasis: IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter.Psoriatic arthritis (with or without methotrexate): IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter.Pustular psoriasis (off-label use): IV: 5 mg/kg at week 0, 2, and 6, followed by 5 mg/kg every 8 weeks for up to 46 weeks (Suguira 2014; Torii 2011).Rheumatoid arthritis (in combination with methotrexate therapy): IV 3 mg/kg at 0, 2, and 6 weeks, followed by 3 mg/kg every 8 weeks thereafter; Remicade doses have ranged from 3 to 10 mg/kg repeated at 4- to 8-week intervals.Ulcerative colitis: IV: 5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter. Doses up to 10 mg/kg were studied in clinical trials with similar efficacy observed with both doses (Rutgeerts 2005); combination therapy with a thiopurine (eg, azathioprine, mercaptopurine) has shown increased efficacy (ACG [Rubin 2019]; Panaccione 2014).Dosage adjustment with heart failure (HF): Weigh risk versus benefits for individual patient:Mild HF (NYHA Class I/II): No dosage adjustment necessary; use with caution and monitor closely for worsening of HF.Moderate to severe (NYHA Class III or IV): ≤5 mg/kg.Dosing: GeriatricRefer to adult dosing.Dosing: PediatricNote: Premedication with antihistamines (H1-antagonist and/or H2-antagonist), acetaminophen and/or corticosteroids may be considered to prevent and/or manage infusion-related reactions: Renflexis (infliximab-abda) and Inflectra (infliximab-dyyb) are approved as biosimilar to Remicade. Approved uses for biosimilar agents may vary (consult product labeling).Crohn disease: Remicade/Inflectra/Renflexis: Children ≥6 years and Adolescents: IV: Initial: 5 mg/kg/dose at
Add Comment